Shenogen enters into an Exclusive License with BioArdis to Develop and Commercialize Novel FGFR4 Kinase Inhibitor for Asian Market

BEIJING China, SHANGHAI, China and SAN DIEGO USA, April 3, 2020 (PR NEWSWIRE) – Shenogen, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in China and beyond, today announced that it has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis Co., […]